Strategic Talent Partnerships EPM Scientific positions itself as a leading specialist talent partner in life sciences, offering permanent, contract and multi-hire solutions across the full product lifecycle from research and development to market launch and pharmacovigilance. Notable collaborations with BioNTech US and Life Sciences PA demonstrate its ability to support large pharma partnerships and cross-border deployments. This makes them a compelling partner for global pharma and biotech clients seeking scalable, end-to-end talent programs to sustain drug development, clinical trials, manufacturing, and commercialization.

Tech Driven Hiring The company’s emphasis on cutting-edge technologies such as 3D printing, gene editing, artificial intelligence, and big data signals demand for specialized talent across data science, automation, regulatory, clinical, and manufacturing roles. This positions EPM Scientific to serve biotech, pharmaceutical, and health-tech organizations undergoing digital transformation and advanced manufacturing initiatives, offering targeted recruitment and multi-hire strategies.

Market Intelligence Value Recent publications including a Commercial Market Update and Salary Guide, alongside a Europe Salary Snapshot, demonstrate the ability to deliver market benchmarking data that helps clients attract and retain top talent. This capability can be offered as a value-add service to inform compensation strategy, speed up offers, and improve candidate quality during engagements.

Global Reach Evidence of a broad geographic footprint, including partnerships in the United States and regional market insights, indicates strong cross-border recruiting capabilities. This makes them well suited for multinational pharma and biotech clients seeking consistent talent delivery across regions.

Scale and Scope A sizeable talent services organization with the ability to support permanent, contract and multi-hire engagements across the full product lifecycle enables scalable partnerships for large product launches, pharmacovigilance expansions, and ongoing R&D staffing needs.